NCT06810544View on ClinicalTrials.gov

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

March 24, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

September 30, 2027

Conditions
Non Small Cell Lung CancerGlioma Glioblastoma MultiformeGlioma, MalignantSolid TumorNon-Small Cell AdenocarcinomaLung CancerBrain Tumor
Interventions
DRUG

TNG456

A selective PRMT5 inhibitor

DRUG

abemaciclib

A kinase inhibitor

Trial Locations (7)

10016

RECRUITING

NYU Langone Health, New York

11065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

20016

RECRUITING

Sibley Memorial Hospital, Washington D.C.

22031

RECRUITING

NEXT Virginia, Fairfax

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

77030

RECRUITING

MD Anderson Cancer Center, Houston

02215

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Tango Therapeutics, Inc.

INDUSTRY